- Home
- IRS vs XERS Comparison
IRS vs XERS Comparison
Compare IRS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- XERS
- Stock Information
- Founded
- IRS 1943
- XERS 2005
- Country
- IRS Argentina
- XERS United States
- Employees
- IRS N/A
- XERS N/A
- Industry
- IRS Homebuilding
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- XERS Health Care
- Exchange
- IRS Nasdaq
- XERS Nasdaq
- Market Cap
- IRS 1.2B
- XERS 1.3B
- IPO Year
- IRS 1994
- XERS 2018
- Fundamental
- Price
- IRS $13.93
- XERS $7.00
- Analyst Decision
- IRS
- XERS Strong Buy
- Analyst Count
- IRS 0
- XERS 7
- Target Price
- IRS N/A
- XERS $10.00
- AVG Volume (30 Days)
- IRS 282.1K
- XERS 3.0M
- Earning Date
- IRS 11-06-2025
- XERS 11-06-2025
- Dividend Yield
- IRS 6.28%
- XERS N/A
- EPS Growth
- IRS N/A
- XERS N/A
- EPS
- IRS 0.42
- XERS N/A
- Revenue
- IRS $370,153,377.00
- XERS $266,137,000.00
- Revenue This Year
- IRS N/A
- XERS $43.89
- Revenue Next Year
- IRS N/A
- XERS $20.40
- P/E Ratio
- IRS $3.37
- XERS N/A
- Revenue Growth
- IRS N/A
- XERS 42.05
- 52 Week Low
- IRS $10.61
- XERS $3.02
- 52 Week High
- IRS $17.67
- XERS $10.08
- Technical
- Relative Strength Index (RSI)
- IRS 43.75
- XERS 33.34
- Support Level
- IRS $15.00
- XERS $6.71
- Resistance Level
- IRS $17.21
- XERS $7.27
- Average True Range (ATR)
- IRS 0.82
- XERS 0.51
- MACD
- IRS -0.13
- XERS -0.15
- Stochastic Oscillator
- IRS 4.08
- XERS 8.46
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).